SG Americas Securities LLC Acquires 28,184 Shares of Bruker Corporation $BRKR

SG Americas Securities LLC boosted its holdings in Bruker Corporation (NASDAQ:BRKR) by 199.8% during the third quarter, HoldingsChannel.com reports. The fund owned 42,293 shares of the medical research company’s stock after purchasing an additional 28,184 shares during the period. SG Americas Securities LLC’s holdings in Bruker were worth $1,374,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BRKR. Nisa Investment Advisors LLC boosted its holdings in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares in the last quarter. Huntington National Bank lifted its position in shares of Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the period. Spire Wealth Management acquired a new stake in Bruker in the 2nd quarter valued at $32,000. Parallel Advisors LLC boosted its stake in Bruker by 63.0% in the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares in the last quarter. Finally, True Wealth Design LLC grew its position in Bruker by 16,716.7% in the second quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 1,003 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Buying and Selling at Bruker

In related news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 15,233 shares of company stock valued at $726,487 over the last three months. Insiders own 27.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BRKR shares. The Goldman Sachs Group assumed coverage on Bruker in a report on Tuesday, December 9th. They set a “sell” rating and a $40.00 price objective for the company. UBS Group lifted their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Redburn Partners set a $60.00 price target on shares of Bruker in a research report on Thursday, November 20th. TD Cowen raised their price objective on shares of Bruker from $42.00 to $53.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Finally, Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $53.36.

Bruker Trading Down 2.2%

BRKR opened at $48.39 on Friday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $61.01. The stock has a market capitalization of $7.35 billion, a PE ratio of -302.44, a PEG ratio of 6.38 and a beta of 1.17. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $47.19 and a two-hundred day moving average price of $40.06.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. Bruker’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.